Efficacy and acceptability of lanreotide autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR

Experimental and Clinical Endocrinology and Diabetes

Volumn 119, Issue 3, 2011, Pages 156-162

  Schopohl, J ^a   Strasburger, C J ^b   Caird, D ^c   Badenhoop, K ^d   Beuschlein, F ^a   Droste, M ^e   Plockinger U ^b   Petersenn, S ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c IDS SCHEER AG   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e Endocrinological Practice Oldenburg ^*  (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

acromegaly; dose intervals; efficacy; lanreotide

Indexed keywords

ANGIOPEPTIN; AUTOGEL; OCTREOTIDE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; ARTICLE; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG PREFERENCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; SINGLE DRUG DOSE;

ACROMEGALY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PATIENT SATISFACTION; PEPTIDES, CYCLIC; QUALITY OF LIFE; QUESTIONNAIRES; SOMATOSTATIN;

EID: 79952440348     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1267244     Document Type: Article

References (34)

1. Antonjonijoan RM, Barbanoj MJ, Cordero JA, etal. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol 2004 56 471-476 (Pubitemid 38455612)
2. Attanasio R, Baldelli R, Pivonello R, etal. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 2003 88 5258-5265 (Pubitemid 37452725)
3. Attanasio R, Lanzi R, Losa M, etal. Effects of lanreotide Autogel on growth hormone, insulin like growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008 14 846-855
4. Baldelli R, Colao A, Razzore P, etal. 2-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000 85 4099-4103 (Pubitemid 32055359)
5. Barbanoj M, Antonijoan R, Morte A, etal. Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency. Clin Pharmacol Therapeut 1999 66 485-491
6. Bronstein M, Musolino N, Jallad R, etal. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after 4 deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol 2005 63 514-519 (Pubitemid 41626745)
7. Caron P, Morange-Ramos I, Cogne M, etal. 3 year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997 82 18-22 (Pubitemid 27021263)
8. Caron PH, Beckers A, Cullen DR, etal. Efficacy of the new long-acting formulation of lanreotide autogel (Lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002 87 99-104 (Pubitemid 34084677)
9. Caron P, Bex M, Cullen DR, etal. Group for Lanreotide Autogel Long-Term Study on Acromegaly. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 2004 60 734-740 (Pubitemid 38788082)
10. Caron P, Cogne M, Raingeard I, etal. Effectiveness and tolerability of 3-year lanreotide Autogel® treatment in patients with acromegaly. Clin Endocrinol 2006 64 209-214
11. Cendros J, Peraire C, Trocoñiz I, etal. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism 2005 54 1276-1278
12. Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis 2008 3 17
13. Chanson P, Borson-Chazot F, Kuhn J-M, etal. Lanreotide Acromegaly Study Group. Control of IGF-1 levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol 2008 69 299-305 (Pubitemid 352009031)
14. Croxtall JD, Scott LJ. Lanreotide Autogel®. A review of its use in the management of acromegaly. Drugs 2008 68 711-723 (Pubitemid 351451549)
15. Elmlinger M, Kühnel W, Weber M, etal. Reference ranges for automated chemiluminescent assays for serum insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004 42 654-664 (Pubitemid 38979144)
16. Freda PU, Katznelson L, van der Lely AJ, etal. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005 90 4465-4473 (Pubitemid 41159328)
17. Giustina A, Chanson P, Bronstein MD, etal. A Consensus on Criteria for Cure of Acromegaly. J Clin Endocrinol Metab 2010 95 7 3141-3148
18. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999 2 29-41
19. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004 89 667-674 (Pubitemid 38269875)
20. Johnson MR, Chowdrey HS, Thomas F, etal. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol 1994 130 229-234 (Pubitemid 24117901)
21. Kauppinen-Makelin R, Sane T, Reunanen A, etal. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005 90 4081-4086 (Pubitemid 41058176)
22. Lucas T, Astorga R. The Spanish-Portuguese MultiCentre Autogel Study Group on Acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol 2006 65 320-326
23. Maiza JC, Vezzosi D, Matta M, etal. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol 2007 67 282-289 (Pubitemid 47076308)
24. Melmed S. Acromegaly. New Engl J Med 2006 355 2558-2573 (Pubitemid 44917504)
25. Melmed S, Colao A, Barkan A, etal. Acromegaly Consensus Group. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab 2009 94 1509-1517
26. Melmed S, Cook D, Schopohl J, etal. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010 13 18-28
27. Mercado M, Borges F, Bouterfa H, etal. SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol 2007 66 859-868 (Pubitemid 47024274)
28. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008 93 2957-2968
29. Mykytuyk M, Khyzhnyak O, Karachentsev Y. Treatment of active acromegaly with the somatostatin analogue lanreotide SR. Endocrine Abstracts 2009 20 222
30. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical cure'. Eur J Endocrinol 2005 152 379-387 (Pubitemid 40439490)
31. Ronchi CL, Boschetti M, Degli Uberti EC, etal. Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol 2007 67 512-519 (Pubitemid 47416307)
32. Trocóniz IF, Cendrós JM, Peraire C, etal. Population pharmacokinetic analysis of lanreotide Autogel® in healthy subjects. Evidence for injection interval of up to 2 months. Clin Pharmacokinet 2009 48 51-62
33. Webb SM, Prieto L, Badia X, etal. Acromegaly quality of life questionnaire (ACROQOL). A new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol 2002 57 251-258 (Pubitemid 34989102)
34. Verhelst JA, Pedroncelli AM, Abs R, etal. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 2000 143 577-584